ISRN Tropical Medicine
Volume 2013 (2013), Article ID 563821, 7 pages
Prevalence and Risk Factors of Hepatitis B and Hepatitis C Virus Infections among Patients with Chronic Liver Diseases in Public Hospitals in Addis Ababa, Ethiopia
Department of Microbiology, Immunology and Parasitology, School of Medicine, Addis Ababa University, P.O. Box 21656, 1000 Addis Ababa, Ethiopia
Received 31 October 2012; Accepted 14 December 2012
Academic Editors: A. Basu, F. J. Carod-Artal, L. Rivas, and A. Talvani
Copyright © 2013 Abel Girma Ayele and Solomon Gebre-Selassie. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and Aims. Hepatitis B and hepatitis C viruses are major public health problems worldwide. The aim of this study was to determine the prevalence and risk factors of hepatitis B and C virus infections in patients with chronic liver diseases in three public hospitals in Addis Ababa City, Ethiopia. Methods. The study was conducted on 120 clinically diagnosed chronic liver disease patients. Possible associated factors with infections by the viruses were collected from patient using questionnaire. Serum was screened for the presence of hepatitis B surface antigen and antihepatitis C virus antibodies using qualitative immunochromatographic method. Results. Hepatitis B surface antigen was detected in 43 (35.8%) and anti-HCV antibody 27 (22.5%) patients clinically diagnosed to have chronic liver diseases. Hepatitis B virus infection was higher in males 29/76 (38.2%) compared to 14/44 (31.8%) females, while antihepatitis C virus antibody was higher in females 13/44 (29.5%) compared to 14/76 (18.4%) males. Of the study participants, 3 (2.5%) had dual hepatitis B and C virus coinfection. Conclusion. The prevalence of hepatitis B surface antigen and anti-HCV antibody was high in patients below 50 years of age. Dental extraction procedure at health facility was associated with hepatitis C virus infection (OR, 2.95; 95% CI, 1.21–7.17, ).
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. Of these viruses, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases worldwide. These viruses are responsible for liver damages ranging from minor disorders to liver cirrhosis and hepatocellular carcinoma (HCC). Approximately 7% of the world’s population (350 million people) are infected with HBV and 3% (170 million people) with HCV . On the basis of the HBV carrier rate, the world can be divided in 3 regions of high, medium, and low endemicity. In Sub-Saharan Africa, the HBV carrier rate is over 8% . Combined HBV and HCV infection is possible because of common modes of viral transmission . HBV is transmitted through exposure to infective blood, semen, other body fluids, or from infected mothers to infants at the time of birth. Transmission may also occur through transfusions of HBV-contaminated blood and blood products, contaminated injections during medical procedures, and through injection drug use. HCV is mostly also transmitted through exposure to infective blood through transfusions of HCV-contaminated blood and blood products, contaminated injections during medical procedures, and through injection drug use. Sexual transmission is also possible .
Chronic liver disease (CLD) results from an inflammatory injury to the liver, which has persisted for six or more months without complete resolution. CLD comprises of a spectrum of disease such as chronic hepatitis, liver cirrhosis, and HCC . It is responsible for over 1.4 million deaths annually and is characterized by permanent inflammatory processes that predispose to liver cancer. About 1-2 million people die annually from HBV-related acute and chronic liver diseases worldwide. The majority of chronic carriers of HBV are found in sub-Saharan Africa. The world health organization (WHO) estimates that there are 350 million people with chronic HBV infection and 170 million people with chronic HCV infection worldwide . The estimated hepatitis B surface antigen (HBsAg) seroprevalence ranges between 0.1%–20% in different parts of the world . In Africa, infections with HBV play a major role in the etiology of most liver diseases. In sub-Saharan Africa, the prevalence of liver disease is high. It was reported that 12% of the hospital admissions and 31% of the mortality in medical wards in Ethiopian hospitals was due to CLD . To ensure the optimal clinical managements of CLD patients, it is important to know the HBV and HCV status of these patients. Studies in Ethiopia on various groups of subjects have demonstrated 2%  and another population based study 0.9% prevalence . However, studies on coinfection of HBV and HCV among chronic liver disease are limited. Thus, this study was undertaken to determine the prevalence and risk factors of HBV and HCV in patients with chronic liver diseases visiting outpatient departments of public hospitals in Addis Ababa.
2. Materials and Methods
2.1. Study Population and Period
A prospective study was conducted in Addis Ababa in 3 public hospitals: Tikur Anbessa, St. Paul, and Zewditu Memorial hospitals in Addis Ababa between November 2010 and May 2011. A total 120 study participants aged ≥18 years with clinically diagnosed CLD were included in the study by convenient sampling technique. Patients were recruited by consecutive basis. The diagnostic criteria for grouping patients as chronic liver disease were based on history, clinical, ultrasound, and impaired liver function tests.
2.2. Data Collection and Processing
Clinically diagnosed patients with CLD who fulfilled the eligibility criteria were interviewed to gather data on sociodemographic and risk factor using predesigned questionnaire after consent was obtained. Five milliliter of blood was collected and serum separated and divided in two aliquots. One aliquot was used for HBsAg screening and the other for anti-HCV antibody screening as per manufacturer instruction.
2.2.1. One Step Test for HBsAg
(Instant HBsAg, Tulip Diagnostics Ltd, India) It utilizes the principle of immunochromatography.
2.2.2. Rapid Anti-HCV Test
One step HCV serum/plasma test strip (Biocare TM Diagnostics, China) was used immunochromatographic direct binding test for the visual detection of HCV antibodies in serum samples.
Data were entered into Epi Info 3.5.1 and analyzed using SPSS 17.0 statistical software. The Chi-square test was utilized in assessing statistical significance of association that could exist between measured variables. value <0.05 was considered as significant. Odds ratio (OR) and 95% confidence interval (CI) were used to measure the strength of association.
3.1. Study Subjects
A total of 125 patients with signs and symptoms of CLD were recruited. Of these, 120 (95.0%) subjects completed the study. Of these, 76 (63.3%) were males and 44 (36.7%) females (male to female ratio of 1.7 : 1). The mean age ± SD for all the study population was years (range = 18–80). Majority, 75.8% were below the age of 50 years, 67 (55.8%) were married, 32 (26.7%) single, 11 (9.2%) divorced, and 10 (8.3%) widow. In relation to residence area, 91 (75.8%) of the participants were urban dwellers. The prevalence of HBsAg and anti-HCV Ab in relation with sociodemographic characteristics is shown in Table 1.
3.2. Magnitude of HBV and HCV Infection
The prevalence of HBsAg in chronic liver disease was 43 (35.8%). The prevalence was higher in males 29/76 (38.2%) than females 14/44 (31.8%) but the difference was not statistical significant (cOR = 1.322; 95% CI: 0.603–2.900; ). The prevalence of HBV was highest, 16/26 (61%) in the age group of 28–37 years but none (0%) in age groups above 68 years (Figure 1). More urban dwellers, 34 (28.3%) were HBsAg positive than rural dwellers, 9 (7.5%). Married patients had prevalence of 23 (19.2%), single were 15 (12.5%) and widows, 3 (1.7%).
Among patients with CLD, 27 (22.5%) were positive for anti-HCV-Ab. The prevalence was higher among females, 13/44 (29.5%) than males 14/76 (18.4%) [cOR = 0.538; 95% CI, 0.226–1.284; ]. The magnitude of HCV by age group was high in the age group of 48–57 years and was lowest above 68 years of age. The prevalence of anti-HCV Ab progressively increased from 1.7% in the age group 18–28 years to 9.2% in the age group 48–57 years then declining to 0% in the age group >68 years (Figure 1). Seropositivity for anti-HCV Ab was high among widows (50%) and divorced 3/8 (37.5%). Three (2.5%) of the patients were positive for both HBsAg and anti-HCV Ab seromarkers. These all were females aged <58 years. All the females who were positive for both seromarkers had history of circumcision and 2 (66.7%) of them had histories of home delivery with traditional birth attendants ().
3.3. Distribution and Factors Associated with HBV and HCV Infections
Of the 120 subjects with CLD, 70(58.3%) had history of admissions to hospitals. Of these, 20 (28.6%) and 16 (22.9%) were positive for HBsAg and anti-HCV-Ab, respectively. Of those who were admitted to hospital, only 25/70 (35.7%) had history of blood transfusion (). Twenty one 21 (30%) had history of either a minor or major surgery. Of those with surgical procedures, 3/21 (19.0%) and 5/21 (23.8%) were positive for HBsAg and anti-HCV-Ab, respectively. Fifty-one (42.5%) patients with CLD had history of dental extraction at health facilities, 41 (34.2%) at home and 8 (6.7%) of them in both at home and health facilities. Of those who had dental extraction at health facility, 18/51 (35.2%) were positive for HBsAg (cOR, 0.960; 95% CI, 0.451–2.044) and 17/51 (33.3%) were positive for anti-HCV-Ab (cOR = 2.95; 95% CI, 1.21–7.17, ). Those who had dental extraction at health facilities were 2.95 time more likely to have infection with HCV than their counter parts and the difference was statistically significant (). Participants who had contact with jaundiced person were 25 (20.8%). From the participants with history of contact with jaundiced person, 11/25 (44%) were positive for HBsAg and 6/25 (24%) were positive for anti-HCV-Ab (OR = 0.461; 95% CI: 0.150–1.422, ) and (OR = 0.342; 95% CI: 0.197–3.17, ), respectively (Table 2). The other risk factors tested were not associated with infection () (Table 3).
In this study, serological analysis revealed high frequency of hepatitis B and C viruses among CLD patients. The prevalence of HBsAg and anti-HCV-antibody in patients with CLD was 35.8% and 22.5%, respectively. Dual infection was observed in 3 (2.5%) patients. The prevalence of HCV in patients with CLD is high compared to the national prevalence of 1.9% in the general population . A recent study in Ethiopia showed a prevalence of 1% and 0% for HBV and HCV, respectively in the general population without any risk for infection . A similar study conducted in India has reported high prevalence of HBV of 55% and HCV of 25.8% in patients with CLD . A study in 97 CLD patients in Pakistan showed that one-fourth (24.7%) were positive for HBsAg and 61.1% for anti HBc .
On HCV showed prevalence of 26% in India  and 75.5% in Egypt . Higher HBV prevalence of 22% was from Sudan in HCC patients  and 30.4% from Pakistan in patients with CLD  were reported.
Age distribution of CLD patients in this study showed that 75.8% of CLD cases were below 50 years of age. A comparable high age distribution (42%) of CLD cases age <50 years was observed by Bukhtiari et al. . The chronic infection with hepatitis viruses leads to slow progressive liver disease. It may end up in cirrhosis, chronic liver failure, and HCC . HBV and HCV share a common route of transmission and can coexist with each other. Coinfection with evidence of chronic HBV and HCV seems to result in more severe liver disease than either infection alone, with an increase risk of liver cancer  and probably an increase risk of fulminant hepatitis when superinfection with HCV on the background of chronic HBV. In our study the detection of co-infection with both HBV and HCV in CLD patients was based on the presence of combination of HBsAg and anti-HCV Ab.
The prevalence of HBV and HCV dual infection in this study was low. Higher findings were reported by other studies in patients on haemodialysis (3.5%), patients undergoing organ transplantation (8%), and injection drug users (42.5%) [21–23]. However, these result may underestimate the true number of people with HBV/HCV co-infection as there is an entity of occult HBV infection in patients with chronic hepatitis C infection . The difference in the magnitude of co-infection among these studies and our study could be attributable to difference in the study population, geographical variation, and difference in methodology. In this study, cases of HCV-associated CLD were lower than HBV-associated cases. Similar pattern was previously reported in Ethiopia with 6.2% and 1.7% . Tessema et al.  showed that the prevalence of HBV and HCV was 4.1% and 0.7%, respectively. In Vietnam, the prevalence of CLD due to HBV and HCV was 47% and 23%, respectively . A higher HBV prevalence of 30.4% from Pakistan in patients with CLD was reported . Contrary to these reports, higher prevalence of HCV to HBV in Pakistan, 64.9% HCV versus 24.7% HBV  higher HCV prevalence of 73.5% was reported among patients with CLD in Egypt . The higher prevalence in these studies could be due to geographical variation and the higher propensity of HCV in causing liver disease than HBV . HBV had higher prevalence in males while HCV was found more in females (). Similar results were reported in studies concerning HBV infection: in Ethiopia 4.9% in males and 3.3% in females , Pakistan 72% in males and 28% in females . Our result was consistent with a study conducted in Madagascar on prevalence of HCV reported higher prevalence of anti-HCV in females than male . However, no known risk exposure by gender for the differences was inferred from this data.
The prevalence of HBV and HCV among CLD patients who had history of either minor or major surgery was 4/23 (17.4%) and 5/23 (21.7%), respectively. However, history of either minor or major surgery could not be inferred from this study as a cause of infection either by HBV or HCV. In comparison, a comparatively low prevalence was reported in a study aimed to determine the seroprevalence of HBV and HCV viral infection in patients undergoing elective eye surgery, only 1.8% and 1.2% were seropositive for HBV and HCV, respectively . Similarly a study on the frequency of HBV and HCV among patients reported a high prevalence, even though it was lower when compared to our finding of HBsAg 3.2% and anti-HCV 2.6% in patients presenting for surgery . In addition, a result which was contrary to our finding was reported in a study by Pasquini et al. . The study revealed exposure to three or more tribal practices, such as ritual scarring or traditional surgery, is associated with an increased risk of HBV infection (OR = 1.7, 95% CI 1.1–2.6). The overall prevalence of HBV and HCV infection in those study participants who had history of blood transfusion was 22.2% and 29.6%, respectively. Two studies on HBV and HCV in blood donors have reported 4.7% and 0.7% (23) and 6.2% and 1.7% in Ethiopia , respectively. With regard to history of blood transfusion, no association was found in acquisition of HBV and HCV infection. This might be explained by the currently implemented screening for potential blood borne pathogens in blood banks.
Univariate analysis showed a strong association between history of dental extraction at health facility and HCV infection. The overall prevalence of HCV among CLD patients who had history of dental extraction at health facility was 17/51 (33.3%) (). Those who had history of dental extraction at health facilities were 2.95 time more likely to have infection with HCV than their counter parts and the difference was statistically significant. This finding agreed with a study conducted in Madagascar  and a strong association of liver disease was found with a history of dental treatment (38%) (OR 2.3; 95% CI: 1.8–3.0). However, no other factors were associated with HCV infection in the study. A study by Ahmad et al.  revealed the frequency of HBV and HCV amongst urban and rural population was 45% and 55%, respectively which is different from this study. Our finding showed greater frequency in urban than rural population. A higher frequency in urban dwellers was also observed in study on the prevalence of HBV in Arsi, Ethiopia (12.6% versus 8.7%) by Pasquini et al. . This higher frequency of infection in urban population may be due to the nature of living in which urban areas are densely populated as compared to rural areas and this might expose urban dwellers for different risk factors. The sociodemographic characteristics have not been significantly associated with acquisition of infection except history of dental extraction at health facility in HCV infection.
The prevalence of HBV and HCV infections among CLD patients in this study is high. Dental extraction at health facilities has 2.95 time association of acquisition of HCV infection than those who do not have history of dental extraction. Thus, all clinically diagnosed CLD patients should be tested for HBV and HCV serostatus. Proper sterilization of dental and surgical instruments must be carried out. To prevent the spread of HBV and HCV, people must be educated about these infections and modes of transmission. The immunization activity against HBV in Ethiopia should be enhanced to full coverage.
Limitation of the Study
Because of the relatively fewer number of cases, all patients with signs and symptoms of CLD were included in the study. Due to resource constraints, this study was unable to conduct confirmatory tests for those positive results and viral load was not performed. The study was did not measure the prevalence of these viruses in the different subgroups of chronic liver disease classification.
The study protocol was cleared by ethical committee of the Department of Microbiology and Parasitology of Addis Ababa University. Written informed consent was obtained from all patients. The study protocol followed the ethical guidelines of the Declaration of Helsinki.
Conflict of Interests
The authors have declared that no conflict of interests exists.
The authors would also like to acknowledge Tikur Anbessa, Zewditu Memorial, and St. Paul Hospitals for permission to conduct the research. They would like to extend their thanks to all of the nurses, physicians, and laboratory staffs for their help in the research process.
- T. A. Shaw-Stiffel, “Chronic hepatitis,” in Principles and Practice of Infectious Diseases, G. L. Mandell, J. E. Bennett, R. Dolin, et al., Eds., pp. 1297–1321, Churchill Livingstone, New York, NY, USA, 5th edition, 2000.
- E. Franco, B. Bagnato, M. G. Marino, C. Meleleo, L. Serino, and L. Zaratti, “Hepatitis B: epidemiology and prevention in developing countries,” World Journal of Hepatology, vol. 4, pp. 74–80, 2012.
- Z. Liu and J. Hou, “Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection,” International Journal of Medical Sciences, vol. 3, no. 2, pp. 57–62, 2006.
- S. C. Smelzer and B. Bare, Brunner and Suddarth's Textbook of Medical Surgical Nursing, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2003.
- A. Laraba, G. Wadzali, B. Sunday, O. Abdulfatai, and S. Fatai, “Hepatitis C virus infection in Nigerians with chronic liver disease,” The Internet Journal of Gastroenterology, vol. 9, no. 1, 2010.
- World Health Organization, Prevention of Hepatitis B in India: An Overview, 2003.
- D. Lavanchy, “Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures,” Journal of Viral Hepatitis, vol. 11, no. 2, pp. 97–107, 2004.
- E. Tsega, Viral hepatitis and CLD in Ethiopia, epidemiological and clinical aspects [Ph.D. thesis], University of Lund, Malmo, Sweden, 1991.
- D. Frommel, R. Tekle-Haimanot, N. Berhe et al., “A survey of antibodies to hepatitis C virus in Ethiopia,” American Journal of Tropical Medicine and Hygiene, vol. 49, no. 4, pp. 435–439, 1993.
- W. Ayele, D. J. Nokes, A. Abebe et al., “Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia,” Journal of Medical Virology, vol. 68, no. 1, pp. 12–17, 2002.
- D. Lavanchy, “Evolving epidemiology of hepatitis C virus,” Clinical Microbiology and Infection, vol. 17, no. 2, pp. 107–115, 2011.
- B. Anagaw, Y. Shiferaw, B. Anagaw, Y. Belyhun, W. Erku, F. Biadglign, et al., “Seroprevalence of hepatitis B and C viruses among medical waste handlers at Gondar town Health institutions, Northwest Ethiopia,” BMC Research Notes, vol. 5, article 55, 2012.
- A. Chakravarti and V. Verma, “Prevalence of hepatitis C and B viral markers in patients with chronic liver disease: a study from northern India,” Indian Journal of Medical Microbiology, vol. 23, no. 4, pp. 273–274, 2005.
- S. K. Issar, B. S. Ramakrishna, B. Ramakrishna, S. Christopher, B. U. Samuel, and T. J. John, “Prevalence and presentation of hepatitis C related chronic liver disease in southern India,” Journal of Tropical Medicine and Hygiene, vol. 98, no. 3, pp. 161–165, 1995.
- I. A. Waked, S. M. Saleh, M. S. Moustafa, A. A. Raouf, D. L. Thomas, and G. T. Strickland, “High prevalence of hepatitis C in Egyptian patients with chronic liver disease,” Gut, vol. 37, no. 1, pp. 105–107, 1995.
- H. M. Mudawi, “Epidemiology of viral hepatitis in Sudan,” Clinical and Experimental Gastroenterology, vol. 1, pp. 9–13, 2008.
- T. S. Khan and F. Rizvi, “Hepatitis B seropositivity among chronic liver disease patients in Hazara division Pakistan,” Journal of Ayub Medical College, Abbottabad, vol. 15, no. 3, pp. 54–55, 2003.
- N. Bukhtiari, T. Hussain, M. Iqbal, A. M. Malik, A. H. Qureshi, and A. Hussain, “Pakistan-US laboratory for sero-epidemiology, Army Medical College, Rawalpindi,” Journal of the Pakistan Medical Association, vol. 53, pp. 136–140, 2003.
- K. Shimotohno, “Hepatitis C virus and its pathogenesis,” Seminars in Cancer Biology, vol. 10, no. 3, pp. 233–240, 2000.
- J. P. Zarski, B. Bohn, A. Bastie et al., “Characteristics of patients with dual infection by hepatitis B and C viruses,” Journal of Hepatology, vol. 28, no. 1, pp. 27–33, 1998.
- G. A. Reddy, K. V. Dakshinamurthy, P. Neelaprasad, T. Gangadhar, and V. Lakshmi, “Prevalence of HBV and HCV dual infection in patients on haemodialysis,” Indian Journal of Medical Microbiology, vol. 23, no. 1, pp. 41–43, 2005.
- A. Aroldi, P. Lampertico, G. Montagnino et al., “Natural history of hepatitis B and C in renal allograft recipients,” Transplantation, vol. 79, no. 9, pp. 1132–1136, 2005.
- J. R. Pallás, C. Fariñas-Álvarez, D. Prieto, and M. Delgado-Rodríguez, “Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users,” European Journal of Epidemiology, vol. 15, no. 8, pp. 699–704, 1999.
- I. Cacciola, T. Pollicino, G. Squadrito, G. Cerenzia, M. E. Orlando, and G. Raimondo, “Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease,” New England Journal of Medicine, vol. 341, no. 1, pp. 22–26, 1999.
- B. Gelaw and Y. Mengistu, “The prevalence of HBV, HCV and malaria parasites among blood donors in Amhara and Tigray regional states,” Ethiopian Journal of Health Development, vol. 22, pp. 3–7, 2008.
- B. Tessema, G. Yismaw, A. Kassu et al., “Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years,” BMC Infectious Diseases, vol. 10, article 111, 2010.
- S. Kakumu, K. Salo, and T. Morisrila, “Prevalence of hepatitis B, hepatitis C and GB virus C / hepatitis G virus infections in liver disease patients and inhabitants in HO Chi Minh, Vietnam,” Journal of Medical Virology, vol. 54, pp. 243–249, 1998.
- C. H. Chen, P. M. Yang, G. T. Huang, H. S. Lee, J. L. Sung, and J. C. Sheu, “Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants,” Journal of the Formosan Medical Association, vol. 106, no. 2, pp. 148–155, 2007.
- I. Ahmad, S. B. Khan, Rahman, H. u, M. H. Khan, and S. Anwar, “Frequency of hepatitis B and hepatitis C among cataract patients,” Gomal Journal of Medical Sciences, vol. 4, pp. 61–64, 2006.
- E. R. Charles, R. Fanjansoa, R. Maherisoa, R. Vaomalala, R. Richter, R. Rindara, et al., “Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar,” BMC Infectious Diseases, vol. 8, article 25, 2008.
- P. Pasquini, L. Bisanti, L. Soldo et al., “Hepatitis B infections in the Arsi region of Ethiopia,” European Journal of Epidemiology, vol. 4, no. 3, pp. 310–313, 1988.